Editorial
Split Viewer
Korean J Hematol 2010; 45(3):
Published online September 30, 2010
https://doi.org/10.5045/kjh.2010.45.3.143
© The Korean Society of Hematology
Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Greipp, PR, San Miguel, J, Durie, BG, et al. International staging system for multiple myeloma. J Clin Oncol, 2005;23;3412-3420.
- Kumar, SK, Mikhael, JR, Buadi, FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc, 2009;84;1095-1110.
- Raja, KR, Kovarova, L, Hajek, R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol, 2010;149;334-351.
- Scudla, V, Pika, T, Budikova, M, et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma, 2010;57;102-110.
- Yang, Y, Yaccoby, S, Liu, W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 2002;100;610-617.
- Seidel, C, Sundan, A, Hjorth, M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood, 2000;95;388-392.
- Oguri, K, Okayama, M. Can syndecan-1 become a prognostic factor in solid tumors?. J Gastroenterol, 2004;39;197-199.
- Kim, JM, Lee, JA, Cho, IS, Ihm, CH. Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study. Korean J Hematol, 2010;45;115-119.
- Lee, JH, Lee, DS, Lee, JJ, et al. Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean multiple myeloma working party. Int J Hematol, 2010;92;52-57.
- Zhou, Y, Barlogie, B, Shaughnessy, JD. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia, 2009;23;1941-1956.
PDF
Standard view
Export citation
Share Article
Editorial
Korean J Hematol 2010; 45(3): 143-144
Published online September 30, 2010 https://doi.org/10.5045/kjh.2010.45.3.143
Copyright © The Korean Society of Hematology.
Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
Je-Jung Lee, M.D.
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Greipp, PR, San Miguel, J, Durie, BG, et al. International staging system for multiple myeloma. J Clin Oncol, 2005;23;3412-3420.
- Kumar, SK, Mikhael, JR, Buadi, FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc, 2009;84;1095-1110.
- Raja, KR, Kovarova, L, Hajek, R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol, 2010;149;334-351.
- Scudla, V, Pika, T, Budikova, M, et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma, 2010;57;102-110.
- Yang, Y, Yaccoby, S, Liu, W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 2002;100;610-617.
- Seidel, C, Sundan, A, Hjorth, M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood, 2000;95;388-392.
- Oguri, K, Okayama, M. Can syndecan-1 become a prognostic factor in solid tumors?. J Gastroenterol, 2004;39;197-199.
- Kim, JM, Lee, JA, Cho, IS, Ihm, CH. Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study. Korean J Hematol, 2010;45;115-119.
- Lee, JH, Lee, DS, Lee, JJ, et al. Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean multiple myeloma working party. Int J Hematol, 2010;92;52-57.
- Zhou, Y, Barlogie, B, Shaughnessy, JD. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia, 2009;23;1941-1956.
Previous Article
